- Patients above the age of 55 consenting to participate in the study.
- Patients with no HLA matched sibling.
patients that have failed BMT.
- Patients with contra-indication to BMT.
- Patients who failed interferon alpha, ARAc and/or Glivec.
- Patients requiring immunosuppressive therapy or corticosteroids.
Investigate the feasibility of allogeneic tumor cell vaccine for patients with resistant CML.